{
  "id": 12174480,
  "title": "Genmab details ovarian cancer data; Lilly's Jaypirca gets a label expansion",
  "url": "https://urgent.news/2026/10/05/genmab-details-ovarian-cancer-data-lillys-jaypirca-gets-a-label",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-05T15:02:14.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/genmab-details-ovarian-cancer-data-lillys-jaypirca-gets-a-label-expansion/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Plus news about Biogen and Gate Bioscience. Genmab shares ovarian cancer data for Rina-S: The drugmaker's FRα-directed ADC attained a 45.9% objective response rate in patients with platinum-resistant ovarian cancer (PROC) ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: Lilly’s Jaypirca approved as first-line CLL therapy",
        "url": "https://urgent.news/2026/10/05/stat-lillys-jaypirca-approved-as-first-line-cll-therapy",
        "published": "2026-10-05T13:55:41.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}